CUA Educational Content

Treatment Evolutions in Prostate Cancer: DNA Damage Response and the Therapeutic Rationale for PARP Inhibition

EDITORIAL COMMITTEE: Fred Saad, Neil Fleshner, Michael Boivin, Michael Kolinsky, Anil Kapoor

At the conclusion of this program, participants should be able to:

  • recognize the DNA damage response (DDR) gene mutations that are involved in prostate cancer, and their implications for therapy
  • integrate genetic testing for patients with prostate cancer into their clinical practice
  • describe the mechanism of action, efficacy, and safety of PARP inhibitors in order to employ these agents for the treatment of prostate cancer with DDR mutations
  • explain the timing, monitoring, and management of adverse events
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

​This program has received financial support from Merck and AstraZeneca Canada.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy